LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Your last searches

  1. AU="Sola Lapeña, Carlos"
  2. AU="Armi M. Chaudhari"

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Blood Donations and Transfusions during the COVID-19 Pandemic in Spain: Impact According to Autonomous Communities and Hospitals.

    García-Erce, José Antonio / Romón-Alonso, Íñigo / Jericó, Carlos / Domingo-Morera, José María / Arroyo-Rodríguez, José Luis / Sola-Lapeña, Carlos / Bueno-Cabrera, José Luis / Juárez-Vela, Raúl / Zalba-Marcos, Saioa / Abad-Motos, Ane / Gea-Caballero, Vicente / Santolalla-Arnedo, Iván / Quintana-Díaz, Manuel

    International journal of environmental research and public health

    2021  Volume 18, Issue 7

    Abstract: Worldwide, the COVID-19 pandemic has caused a decline in blood donations, between 30% and 70% in some of the most affected countries. In Spain, during the initial eight weeks after the State of Emergency was decreed on 14 March 2020, in the weekly ... ...

    Abstract Worldwide, the COVID-19 pandemic has caused a decline in blood donations, between 30% and 70% in some of the most affected countries. In Spain, during the initial eight weeks after the State of Emergency was decreed on 14 March 2020, in the weekly reports of the Health Ministry, an average decrease of 20% was observed between 11 and week 25 compared with the 2018 donation. We aimed to investigate the impact of the COVID-19 pandemic on blood donations and blood distribution in four autonomous communities, and to explore the evolution of the consumption of blood components (BCs) in ten hospitals of six autonomous communities. We performed a prospective study of grouped cohorts on the donation and distribution of blood in four regional transfusion centers in four autonomous communities in Spain, and a retrospective study of the consumption of blood components in ten hospitals in six autonomous communities. Regarding donations, there was no significant decrease in donations, with differences between autonomous communities, which started between 1 and 15 March 2020 (-11%). The increase in donations in phase II (from 26 May 2020) stands out. Regarding consumption, there was a significant reduction in the consumption of packed red blood cells (RBCs) (24.5%), plasma (45.3%), and platelets (25.3%) in the central period (16 March-10 May). The reduction in the consumption of RBCs was significant in the period from 1-15 March. Conclusions: The COVID-19 pandemic has affected the donation and consumption of BCs.
    MeSH term(s) Blood Donors ; COVID-19 ; Hospitals ; Humans ; Pandemics ; Prospective Studies ; Retrospective Studies ; SARS-CoV-2 ; Spain/epidemiology
    Language English
    Publishing date 2021-03-27
    Publishing country Switzerland
    Document type Journal Article
    ISSN 1660-4601
    ISSN (online) 1660-4601
    DOI 10.3390/ijerph18073480
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Pathogen reduction with methylene blue does not have an impact on the clinical effectiveness of COVID-19 convalescent plasma.

    Romera Martínez, Irene / Bueno Cabrera, José Luis / Domingo-Morera, José María / López Aguilar, Juan Carlos / Villegas Da Ros, Carolina / García Erce, José Antonio / Sáez Serrano, Isabel / Flores Ballester, Elena / Maglio, Laura Analía / Arbona Castaño, Cristina / Sola Lapeña, Carlos / Guerra Domínguez, Luisa / Berberana Fernández, Margarita / Madrigal Sánchez, María Elena / Rubio Batllés, Martín / Pérez-Olmeda, Mayte / Ramos-Martínez, Antonio / Velasco-Iglesias, Ana / Avendaño-Solá, Cristina /
    Duarte, Rafael F

    Vox sanguinis

    2023  Volume 118, Issue 4, Page(s) 296–300

    Abstract: Background and objectives: There is a concern about a possible deleterious effect of pathogen reduction (PR) with methylene blue (MB) on the function of immunoglobulins of COVID-19 convalescent plasma (CCP). We have evaluated whether MB-treated CCP is ... ...

    Abstract Background and objectives: There is a concern about a possible deleterious effect of pathogen reduction (PR) with methylene blue (MB) on the function of immunoglobulins of COVID-19 convalescent plasma (CCP). We have evaluated whether MB-treated CCP is associated with a poorer clinical response compared to other inactivation systems at the ConPlas-19 clinical trial.
    Materials and methods: This was an ad hoc sub-study of the ConPlas-19 clinical trial comparing the proportion of patients transfused with MB-treated CCP who had a worsening of respiration versus those treated with amotosalen (AM) or riboflavin (RB).
    Results: One-hundred and seventy-five inpatients with SARS-CoV-2 pneumonia were transfused with a single CCP unit. The inactivation system of the CCP units transfused was MB in 90 patients (51.4%), RB in 60 (34.3%) and AM in 25 (14.3%). Five out of 90 patients (5.6%) transfused with MB-treated CCP had worsening respiration compared to 9 out of 85 patients (10.6%) treated with alternative PR methods (p = 0.220). Of note, MB showed a trend towards a lower rate of respiratory progressions at 28 days (risk ratio, 0.52; 95% confidence interval, 0.18-1.50).
    Conclusion: Our data suggest that MB-treated CCP does not provide a worse clinical outcome compared to the other PR methods for the treatment of COVID-19.
    MeSH term(s) Humans ; COVID-19/therapy ; COVID-19 Serotherapy ; Immunization, Passive/methods ; Methylene Blue/pharmacology ; Methylene Blue/therapeutic use ; SARS-CoV-2 ; Treatment Outcome
    Chemical Substances Methylene Blue (T42P99266K)
    Language English
    Publishing date 2023-02-03
    Publishing country England
    Document type Clinical Trial ; Journal Article
    ZDB-ID 80313-3
    ISSN 1423-0410 ; 0042-9007
    ISSN (online) 1423-0410
    ISSN 0042-9007
    DOI 10.1111/vox.13406
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top